Trial · NCT07103694
Registered outcomes61
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 61
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | effectiveness of innovative drugs as migraine prophylaxis | the assessment will be conducted at 4 weeks from treatment initiation | reduction in the number of monthly migraine days compared to the baseline average recorded in the three months preceding treatment |
| Primary | effectiveness of innovative drugs as migraine prophylaxis | the assessment will be conducted at 8 weeks from treatment initiation | reduction in the number of monthly migraine days compared to the baseline average recorded in the three months preceding treatment |
| Primary | effectiveness of innovative drug as migraine prophylaxis | the assessment will be conducted at 12 weeks from treatment initiation | reduction in the number of monthly migraine days compared to the baseline average recorded in the three months preceding treatment |
| Primary | effectiveness of innovative drugs as migraine prophylaxis | the assessment will be conducted at 24 weeks from treatment initiation | reduction in the number of monthly migraine days compared to the baseline average recorded in the three months preceding treatment |
| Primary | effectiveness of innovative drugs as migraine prophylaxis | the assessment will be conducted at 48 weeks from treatment initiation | reduction in the number of monthly migraine days compared to the baseline average recorded in the three months preceding treatment |
| Primary | 2 hour-pain freedom | 2 hours | Percentage of patients reporting complete pain relief within 2 hours after taking the innovative drug for migraine attack |
| Secondary | safety and tolerability of innovative drugs as migraine prophylaxis | the assessment will be conducted at 48 weeks from treatment initiation | type and number of adverse events occurring during the study period (event details, duration, severity and action taken) |
| Secondary | impact of innovative drugs as migraine prophylaxis on symptomatic medication use and medication overuse headache | the assessment will be conducted at 48 weeks from treatment initiation | reduction in the average monthly consumption of analgesics in patients undergoing treatment with innovative drugs |
| Secondary | impact of innovative drugs as migraine prophylaxis on migraine symptoms | the assessment will be conducted at 4 weeks from treatment initiation | mean change in perceived pain intensity during a migraine attack (measured using the Numerical Rating Scale, score range 0-10) compared to the pre-treatment period |
| Secondary | impact of innovative drugs as migraine prophylaxis on migraine symptoms | the assessment will be conducted at 8 weeks from treatment initiation | mean change in perceived pain intensity during a migraine attack (measured using the Numerical Rating Scale, score range 0-10) compared to the pre-treatment period |
| Secondary | impact of innovative drugs as migraine prophylaxis on migraine symptoms | the assessment will be conducted at 12 weeks from treatment initiation | mean change in perceived pain intensity during a migraine attack (measured using the Numerical Rating Scale, score range 0-10) compared to the pre-treatment period |
| Secondary | impact of innovative drugs as migraine prophylaxis on migraine symptoms | the assessment will be conducted at 24 weeks from treatment initiation | mean change in perceived pain intensity during a migraine attack (measured using the Numerical Rating Scale, score range 0-10) compared to the pre-treatment period |
| Secondary | impact of innovative drugs as migraine prophylaxis on migraine symptoms | the assessment will be conducted at 48 weeks from treatment initiation | mean change in perceived pain intensity during a migraine attack (measured using the Numerical Rating Scale, score range 0-10) compared to the pre-treatment period |
| Secondary | impact of innovative drugs as migraine prophylaxis on migraine-related disability | the assessment will be conducted at 4 weeks from treatment initiation | mean change in Headache Impact Test 6-TM scores (score range 36-78) before treatment |
| Secondary | impact of innovative drugs as migraine prophylaxis on migraine-related disability | the assessment will be conducted at 8 weeks from treatment initiation | mean change in Headache Impact Test 6-TM scores (score range 36-78) before treatment |
| Secondary | impact of innovative drugs as migraine prophylaxis on migraine-related disability | the assessment will be conducted at 12 weeks from treatment initiation | mean change in Headache Impact Test 6-TM scores (score range 36-78) before treatment |
| Secondary | impact of innovative drugs as migraine prophylaxis on migraine-related disability | the assessment will be conducted at 24 weeks from treatment initiation | mean change in Headache Impact Test 6-TM scores (score range 36-78) before treatment |
| Secondary | impact of innovative drugs as migraine prophylaxis on migraine-related disability | the assessment will be conducted at 48 weeks from treatment initiation | mean change in Headache Impact Test 6-TM scores (score range 36-78) before treatment |
| Secondary | impact of innovative drugs as migraine prophylaxis on migraine-related disability | the assessment will be conducted at 12 weeks from treatment initiation | mean change in Migraine Disability Assessment Score Questionnaire (grade I: 0-5; grade II: 6-10; grade III: 11-20; grade IV\>21) before treatment |
| Secondary | impact of innovative drugs as migraine prophylaxis on migraine-related disability | the assessment will be conducted at 24 weeks from treatment initiation | mean change in Migraine Disability Assessment Score Questionnaire (grade I: 0-5; grade II: 6-10; grade III: 11-20; grade IV\>21) before treatment |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07103694/registered